Rabbit Anti-Human VEGFR-2/KDR

Slide this table

Size50 µg
Price195 €
CategoryPolyclonal Antibody
Clone Nr.Rabbit IgG
Species ReactivityHuman
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
PreparationProduced from sera of rabbits immunized with highly pure recombinant human soluble extracellular domain of KDR (110 kDa) as the immunizing antigen. Anti-human VEGFR-2/KDR was purified by antigen-affinity chromatography with immobilized recombinant soluble VEGFR-2/KDR. The antibody is identical with the former described antibody R212 (see Lit.)
AntigenRecombinant human KDR (D1-7) (RT #S01-001)
ApplicationWB, E, IP
Synonymsvascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor
DescriptionVEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.
Uniprot IDP35968
Protein RefSeqNP_002244.1
mRNA RefSeqNM_002253.2



  1. Lack of Evidence for the Direct Activation of Endothelial Cells by Adult Female and Microfilarial Excretory-Secretory Products. T. Weinkopff and P. Lammie, PLoS One. 2011; 6(8): e22282.
  2. The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. S. Dedieu et al., BMC Med. 2010; 8: 19.

All prices plus VAT + possible delivery charges